The reason why immune checkpoint inhibitors are effective when combined with anti-angiogenesis drugs in anti-tumor therapy is that immune checkpoint inhibitors can transform the immune microenvironment that favors tumor growth into one that inhibits tumor growth, while anti-angiogenesis drugs can cut off the nutrient supply for tumor growth, which cannot be separated from the VEGF secreted by the tumor itself. Here, VEGFA is linked to neoplasm.